Wells sees potential upside after Glaukos’ iDose repeat dosing label approved

Wells Fargo notes that Glaukos (GKOS) has announced FDA approval of its repeat dosing label for iDose, in line with the firm’s expectations. Label appears broad though with some corneal-safety limits. Overall, Wells views this as supportive of the long-term iDose annuity model. The firm has an Overweight rating on the shares with a price target of $122.

Claim 50% Off TipRanks Premium

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions

Stay ahead of the market with the latest news and analysis and maximize your portfolio’s potential

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on GKOS:

Disclaimer & DisclosureReport an Issue

Glaukos announces FDA approval of iDose TR NDA labeling supplement

Glaukos price target raised to $160 from $115 at Stifel

Glaukos Advances Phase 3 Glaucoma Implant Trial, Keeping GKOS in Focus for Investors

Glaukos falls -8.5%

Video: Wells Fargo dips as big bank earnings continue